Compare · KLRA vs NVO
KLRA vs NVO
Side-by-side comparison of Kailera Therapeutics Inc. (KLRA) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both KLRA and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.82B, about 66.5x KLRA ($2.76B).
- Over the past year, KLRA is down 14.3% and NVO is down 34.2% - KLRA leads by 20.0 points.
- KLRA has been more active in the news (22 items in the past 4 weeks vs 5 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 0 for KLRA).
- Company
- Kailera Therapeutics Inc.
- Novo Nordisk A/S
- Price
- $22.42-10.43%
- $41.18+6.93%
- Market cap
- $2.76B
- $183.82B
- 1M return
- -14.28%
- +13.32%
- 1Y return
- -14.28%
- -34.24%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2026
- News (4w)
- 22
- 5
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest KLRA
- SEC Form SCHEDULE 13D filed by Kailera Therapeutics Inc.
- SEC Form SCHEDULE 13D filed by Kailera Therapeutics Inc.
- SEC Form 4 filed by Rtw Investments, Lp
- SEC Form 4 filed by Jiangsu Hengrui Pharmaceuticals Co., Ltd.
- Hengrui Pharma Reports Q1 2026 Results with Revenue and Net Profit Growth
- SEC Form 4 filed by Bain Capital Investors Llc
- SEC Form 4 filed by Koppel Adam
- SEC Form 4 filed by Bain Capital Life Sciences Investors, Llc
- SEC Form 4 filed by Kaplan Andrew T.
- SEC Form 4 filed by Cloghessy Paula
Latest NVO
- The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Wolfe Research initiated coverage on Novo Nordisk A/S